Sex Differences in Glioblastoma Immunotherapy Response

Area of Science:

• Neuro-oncology
• Immunology
• Genetics

Background:

• Glioblastoma (GBM) is the most common malignant brain tumor, notoriously difficult to treat.
• GBM shares aberrant immune responses with other neurological disorders, making immune mechanisms a priority.
• Current immunotherapies show limited efficacy in GBM, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review and present sex differences in glioblastoma (GBM) pathogenesis and immune responses.
• To highlight potential sex-specific cellular and molecular mechanisms driving GBM.
• To explore how these sex differences can inform the development of next-generation GBM immunotherapies.

Main Methods:

• Mini-review of existing epidemiological and scientific literature.
• Analysis of sex-based differences in GBM prevalence, genetic aberrations, and cellular programs.
• Examination of sex-specific immune responses relevant to GBM.

Main Results:

• Epidemiological data indicate a higher prevalence of GBM in males.
• Studies reveal sex-based differences in genetic aberrations and cellular programs within GBM.
• Sex differences are also evident in immune responses, impacting GBM growth and treatment.

Conclusions:

• Sex differences represent a significant, yet understudied, factor in glioblastoma (GBM) pathogenesis.
• Understanding these sex-specific mechanisms is critical for improving GBM treatment and immunotherapy efficacy.
• Insights from GBM sex differences may extend to other cancers and neurological disorders, guiding future therapeutic development.